93 results
424B5
ARAV
Aravive Inc
28 Jun 23
Prospectus supplement for primary offering
6:01am
diseases, including cancer and fibrosis.
Batiraxcept (formerly AVB-500), is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling
424B3
ARAV
Aravive Inc
29 Nov 22
Prospectus supplement
4:05pm
product candidate, batiraxcept (formerly AVB-500), is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway. By capturing
424B5
lr2ak4hes25psida
31 Mar 22
Prospectus supplement for primary offering
6:06am
424B3
pgm20h7xpxsi q26o
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-99.1
k93cgxd xi5fmav
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
ccepz 414
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
t83khttrl5ewy thu
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
vkir1jq91 apej
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
a8o sezxk6r9dc9hkipu
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am